Clinical Trial Update: Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. [Phase 2]

View source ↗

Summary

A Phase 2 trial is investigating upfront trastuzumab deruxtecan with capecitabine and bevacizumab for HER-2 positive metastatic colorectal cancer and is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: Gruppo Oncologico del Nord-Ovest | Conditions: Colorectal Cancer, Colorectal Adenocarcinoma | Phase 2 | Status: RECRUITING